Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
10:55am, Tuesday, 08'th Oct 2024
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
09:15am, Friday, 04'th Oct 2024
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
02:08pm, Tuesday, 01'st Oct 2024
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more t
Capricor Therapeutics is up over 100%, Could Rise Even Higher
08:23am, Monday, 30'th Sep 2024
Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surge
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
09:15am, Sunday, 29'th Sep 2024
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
04:35pm, Tuesday, 24'th Sep 2024
BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
08:40am, Tuesday, 24'th Sep 2024
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
09:25am, Monday, 23'rd Sep 2024
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Doub
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
08:30am, Friday, 06'th Sep 2024
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
10:43pm, Thursday, 08'th Aug 2024
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Linda Marban – Chief Executive Officer AJ Bergmann – Chief Financial Offi
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
06:25pm, Wednesday, 07'th Aug 2024
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago.
CORRECTION: Capricor Therapeutics
10:30am, Tuesday, 25'th Jun 2024
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
08:30am, Tuesday, 25'th Jun 2024
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going
01:44pm, Monday, 17'th Jun 2024
Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1
